Invivyd (NASDAQ:IVVD) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $15.00 price objective on the stock.

Invivyd Price Performance

Shares of Invivyd stock opened at $0.91 on Tuesday. The stock has a market capitalization of $108.21 million, a price-to-earnings ratio of -0.48 and a beta of 0.63. The firm’s fifty day simple moving average is $0.99 and its 200-day simple moving average is $1.41. Invivyd has a 12 month low of $0.81 and a 12 month high of $5.20.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. Analysts anticipate that Invivyd will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On Invivyd

Several institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its stake in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Invivyd during the 2nd quarter worth $115,000. Dimension Capital Management LLC boosted its position in shares of Invivyd by 243.3% during the 2nd quarter. Dimension Capital Management LLC now owns 189,871 shares of the company’s stock worth $209,000 after purchasing an additional 134,571 shares in the last quarter. Duquesne Family Office LLC purchased a new stake in shares of Invivyd during the 2nd quarter worth $629,000. Finally, Marshall Wace LLP boosted its position in shares of Invivyd by 4.2% during the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.